Conolidine’s analgesic results stem from its conversation with non-opioid pain pathways. As opposed to opioids, which bind to µ-opioid receptors in the central anxious procedure, conolidine modulates alternate molecular targets. A Science Advances research found that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://tuckerh268qle5.elbloglibre.com/profile